Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

NCT05751733 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

258

Enrollment

OTHER

Sponsor class

Conditions

Gastrointestinal Stromal Tumors

Interventions

DRUG: Apatinib Mesylate
DRUG: Sunitinib, Imatinib dosage, Dasatinib, Reveratinib

Sponsor

Xiangya Hospital of Central South University

Collaborators

[object Object]